P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice

Pharmaceutical Research

Volumn 16, Issue 8, 1999, Pages 1213-1218

  Yokogawa, Koichi ^a   Takahashi, Megumi ^a   Tamai, Ikumi ^a,c   Konishi, Hiroko ^a   Nomura, Masaaki ^a   Moritani, Shuzo ^b   Miyamoto, Ken Ichi ^a   Tsuji, Akira ^a,c  

^a KANAZAWA UNIVERSITY   (Japan)

^b FUKUI PREFECTURAL UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Brain distribution; Disposition kinetics; Mdr1a knockout mice; P glycoprotein; Tacrolimus

Indexed keywords

GLYCOPROTEIN P; IMMUNOPHILIN; TACROLIMUS;

ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG TRANSPORT; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; LIVER CLEARANCE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; BILIARY TRACT; BRAIN; DIGESTIVE SYSTEM; DRUG RESISTANCE, MULTIPLE; IMMUNOSUPPRESSIVE AGENTS; KINETICS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-GLYCOPROTEIN; TACROLIMUS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0032807119     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018993312773     Document Type: Article

References (30)

1. 1. F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738 (1987).
2. 2. E. Georges, G. Bradley, J. Gariepy, and V. Ling. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc. Natl. Acad. Sci. USA 87:152-156 (1990).
3. 3. A. Tsuji, T. Terasaki, Y. Takabatake, Y. Tenda, I. Tamai, T. Yamashita, S. Moritani, T. Tsuruo, and J. Yamashita. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1427-1437 (1992).
4. 4. A. De Vaut and P. Gros. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell. Biol. 10:1652-1663 (1990).
5. 5. P. Borst, A. H. Schinkel, J. J. M. Smit, E. Wagenaar, L. van Deemter, A. J. Smith, E. W. H. M. Eijdems, F. Baas, and G. J. R. Zaman. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoprotein in mammals. Pharmac. Ther. 60:289-299 (1993).
6. 6. A. H. Schinkel, J. J. M. Smit, O. van Telligen, J. H. Beijinen, E. Wagenaar, L. van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag, H. P. te Riele, A. J. M. Berns, and P. Brrst. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502 (1994).
7. 7. A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. Mol, and P. Borst. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-1705 (1995).
8. 8. A. Tsuji and I. Tamai, I. Blood-brain barrier function of P-glycoprotein. Adv. Drug Deliv. Rev. 25:287-298 (1997).
9. 9. K. Ohara, R. Billington, R. W. James, G. A. Dean, M. Nishiyama, and H. Noguchi. Toxicologic evaluation of FK506. Transplant. Proc. 22:83-86 (1990).
10. 10. B. A. Appignani, R. A. Bhadelia, S. C. Blacklow, A. K. Wang, S. F. Roland, and R. B. Freeman. Neuroimaging finding in patients on immunosuppressive therapy: Experience with tacrolimus toxicity. Am. J. Roentgenol. 166:683-688 (1996).
11. 11. J. Sharkey and S. P. Butcher. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischemia. Nature (London) 371:336-339 (1994).
12. 12. S. P. Butcher, D. C. Henshall, Y. Teramura, K. Iwasaki, and J. Sharkey. Neuroprotective actions of FK506 in experimental stroke: In vivo evidence against an antiexcitotoxic mechanism. J. Neurosci. 17:6939-6946 (1997).
13. 13. M. Naito, T. Ohhara, A. Yamazaki, T. Danki, and T. Tsuruo, Reversal of multidrug resistance by an immunosuppressive agent FK506. Cancer Chemother. Pharmacol. 29:195-200 (1992).
14. 14. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano. Human P-glycoprotein transports cyclosporine A and FK506. J. Biol. Chem. 267:6077-6080 (1993).
15. 15. M. Kobayashi, K. Tamura, N. Katayama, K. Nakamura, K. Nagase, K. Hane, T. Tutumi, M. Niwa, H. Tanaka, K. Iwasaki, and M. Kohsaka FK506 assay past and present - characteristics of FK506 ELISA. Transplant. Proc. 23:2725-2729 (1991).
16. 16. K. Yamaoka, T. Nakagawa, and T. Uno. Moment analysis for disposition kinetics of several cephalosporin antibiotics in rats. J. Pharm. Pharmacol. 35:19-22 (1983).
17. 17. R. G. Blasberg, J. D. Fenstermacher, and C. S. Patlak. Transport of α-aminoisobutyric acid across brain capillary and cellular membranes. J. Cereb. Blood Flow Metab. 3:8-32 (1983).
18. 18. U. Christians, C. Kruse, R. Kownatzki, H. M. Schiebel, R. Schwinzer, M. Sattler, R. Schottmann, A. Linck, V. M. F. Almeida, F. Braun, F., and K. Fr. Sewing. Measurement of FK506 by HPLC and isolation and characterization of its metabolites. Transplant. Proc. 23:940-941 (1991).
19. 19. T. Shiraga, H. Matsuda, K. Nagase, K. Iwasaki, K. Noda, H. Yamazaki, T. Shimada, and Y. Funae. Metabolism of FK506, a potent immunosappressive agent, by cytochrome P450 3A enzymes in rat, dog, and human liver microsomes. Biochem. Pharmacol. 47:7275 (1994).
20. 20. A. M. Alak. Measurement of tacrolimus (FK506) and its metabolites: A review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. Ther. Drug Munitor. 19:338-351 (1997).
21. 21. A. M. Alak and S. Moy. Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. Transplant. Proc. 29:2487-2490 (1997).
22. 22. K. Iwasaki, T. Shiraga, K. Nagase, K. Hirano, K. Nozaki, and K. Noda. Pharmacokinetic study of FK506 in the rat. Transplant. Proc. 23:2757-2759 (1991).
23. 23. K. Iwasaki, T. Shiraga, H. Matsuda, Y. Teramura, A. Kawamura, T. Hata, S. Ninimiya, and Y. Esumi. Absorption, distribution, metabolism and excretion of tacrolimus (FK506) in the rat. Xenobio. Metabol. Dispos. 13:259-265 (1998).
24. 24. R. Venkataramanan, A. Swaminatha, T. Prasad, A. Jain, S. Zuckerman, V. Warty, J. McMichael, J. Lever, G. Burckart, and T. Starzl. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29:404-430 (1995).
25. 25. N. Takeguchi, K. Ichimura, M. Koike, W. Matsui, T. Kashiwagura, and K. Kawahara. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. Transplantation 55:646-650 (1993).
26. 26. F. Ichimura, K. Yokogawa, T. Yamana, A. Tsuji, and Y. Mizukami. Physiological pharmacokinetic model for pentazocine. I. Tissue distribution and elimination in the rat. Int. J. Pharm. 15:321-333 (1983).
27. 27. J. Liu, J. D. Farmer, W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiver. Calcineurin is a common target of cyclophillin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815 (1991).
28. 28. J. P. Steiner, T. M. Dawson, M. Fotuhi, C. E. Glatt, A. M. Snowman, N. Cohen, and S. H. Snyder. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature (London) 358:584-587 (1992).
29. 29. M. Asami, T. Kuno, H. Mukai, and C. Tanaka. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. Biochem. Biophys. Res. Commun. 192:1388-1394 (1993).
30. 30. T. Terao, E. Hisanaga, Y. Sai, I. Tamai, and A. Tsuji. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 48:1083-1089 (1996).